Rossari Biotech Past Earnings Performance
Past criteria checks 5/6
Rossari Biotech has been growing earnings at an average annual rate of 16%, while the Chemicals industry saw earnings growing at 14.6% annually. Revenues have been growing at an average rate of 13.4% per year. Rossari Biotech's return on equity is 12.4%, and it has net margins of 7.2%.
Key information
16.0%
Earnings growth rate
13.5%
EPS growth rate
| Chemicals Industry Growth | 17.7% |
| Revenue growth rate | 13.4% |
| Return on equity | 12.4% |
| Net Margin | 7.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Why We Think Rossari Biotech Limited's (NSE:ROSSARI) CEO Compensation Is Not Excessive At All
Aug 17
Is Rossari Biotech (NSE:ROSSARI) Using Too Much Debt?
Jun 14Rossari Biotech's (NSE:ROSSARI) Solid Profits Have Weak Fundamentals
May 07Analyst Estimates: Here's What Brokers Think Of Rossari Biotech Limited (NSE:ROSSARI) After Its Annual Report
May 03One Analyst Just Shaved Their Rossari Biotech Limited (NSE:ROSSARI) Forecasts Dramatically
Feb 10Returns On Capital At Rossari Biotech (NSE:ROSSARI) Paint A Concerning Picture
Sep 23Returns On Capital Signal Tricky Times Ahead For Rossari Biotech (NSE:ROSSARI)
Apr 06Need To Know: Analysts Are Much More Bullish On Rossari Biotech Limited (NSE:ROSSARI) Revenues
Feb 19Rossari Biotech Limited Just Beat Revenue Estimates By 6.8%
Feb 17I Ran A Stock Scan For Earnings Growth And Rossari Biotech (NSE:ROSSARI) Passed With Ease
Feb 10Capital Allocation Trends At Rossari Biotech (NSE:ROSSARI) Aren't Ideal
Nov 24With EPS Growth And More, Rossari Biotech (NSE:ROSSARI) Is Interesting
Oct 12Is Rossari Biotech Limited's (NSE:ROSSARI) Latest Stock Performance Being Led By Its Strong Fundamentals?
Dec 17Rossari Biotech (NSE:ROSSARI) Is Growing Earnings But Are They A Good Guide?
Oct 26
Revenue & Expenses Breakdown
How Rossari Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 19,245 | 1,388 | 1,189 | 0 |
| 30 Jun 24 | 19,096 | 1,364 | 1,072 | 0 |
| 31 Mar 24 | 18,306 | 1,307 | 1,098 | 0 |
| 31 Dec 23 | 17,643 | 1,255 | 1,084 | 0 |
| 30 Sep 23 | 16,898 | 1,168 | 1,065 | 0 |
| 30 Jun 23 | 16,318 | 1,078 | 1,031 | 0 |
| 31 Mar 23 | 16,559 | 1,073 | 1,039 | 0 |
| 31 Dec 22 | 16,883 | 1,027 | 997 | 0 |
| 30 Sep 22 | 17,275 | 995 | 957 | 0 |
| 30 Jun 22 | 16,866 | 1,018 | 855 | 0 |
| 31 Mar 22 | 14,830 | 977 | 735 | 0 |
| 31 Dec 21 | 12,623 | 957 | 610 | 0 |
| 30 Sep 21 | 10,438 | 948 | 516 | 0 |
| 30 Jun 21 | 8,310 | 892 | 462 | 0 |
| 31 Mar 21 | 7,093 | 802 | 456 | 0 |
| 31 Dec 20 | 6,507 | 729 | 423 | 0 |
| 30 Sep 20 | 6,031 | 695 | 415 | 0 |
| 30 Jun 20 | 5,818 | 666 | 389 | 0 |
| 31 Mar 20 | 6,001 | 653 | 396 | 0 |
| 31 Mar 19 | 5,162 | 457 | 301 | 0 |
| 31 Mar 18 | 2,922 | 254 | 213 | 0 |
| 31 Mar 17 | 2,350 | 143 | 195 | 0 |
Quality Earnings: ROSSARI has high quality earnings.
Growing Profit Margin: ROSSARI's current net profit margins (7.2%) are higher than last year (6.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ROSSARI's earnings have grown by 16% per year over the past 5 years.
Accelerating Growth: ROSSARI's earnings growth over the past year (18.8%) exceeds its 5-year average (16% per year).
Earnings vs Industry: ROSSARI earnings growth over the past year (18.8%) exceeded the Chemicals industry 8%.
Return on Equity
High ROE: ROSSARI's Return on Equity (12.4%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 06:55 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rossari Biotech Limited is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Bhawana Israni | Anand Rathi Shares and Stock Brokers Limited |
| Rohit Nagraj | Centrum Broking Limited |